[1. ANGELI P., MERKEL C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol. 2008; 48(Suppl 1):S93-103.10.1016/j.jhep.2008.01.010]Search in Google Scholar
[2. PHAM PT., PHAM PC., RASTOGI A., WILKINSON AH. Review article: current management of renal dysfunction in the cirrhotic patient. Aliment Pharmacol Ther. 2005; 21(8):949-61.10.1111/j.1365-2036.2005.02357.x]Search in Google Scholar
[3. CÁRDENAS A., GINÈS P. Hepatorenal syndrome. Clin Liver Dis. 2006; 10(2):371-85.10.1016/j.cld.2006.05.006]Search in Google Scholar
[4. GINÈS A., ESCORSELL A., GINÈS P., SALÓ J., JIMÉNEZ W., INGLADA L., et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993; 105(1):229-36.10.1016/0016-5085(93)90031-7]Search in Google Scholar
[5. ARROYO V., TERRA C., GINÈS P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol. 2007; 46(5):935-46.10.1016/j.jhep.2007.02.001]Search in Google Scholar
[6. TSOCHATZIS EA., BOSCH J., BURROUGHS AK. Liver cirrhosis. Lancet. 2014; 383(9930):1749-61.10.1016/S0140-6736(14)60121-5]Search in Google Scholar
[7. ARROYO V., GINÈS P., GERBES AL., DUDLEY FJ., GENTILINI P., LAFFI G., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996; 23(1):164-76.10.1002/hep.510230122]Search in Google Scholar
[8. SALERNO F., GERBES A., GINÈS P., WONG F., ARROYO V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007; 56(9):1310-8.]Search in Google Scholar
[9. CHOLONGITAS E., CALVARUSO V., SENZOLO M., PATCH D., SHAW S., O'BEIRNE J., et al. RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. J Gastroenterol Hepatol. 2009; 24(10):1639-47.10.1111/j.1440-1746.2009.05908.x]Search in Google Scholar
[10. MYERS RP., LEE SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl. 2000; 6(4 Suppl 1):S44-52.10.1002/lt.500060510]Search in Google Scholar
[11. BERNARDI M., RUBBOLI A., TREVISANI F., CANCELLIERI C., LIGABUE A., BARALDINI M., et al. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J Hepatol. 1991; 12(2):207-16.10.1016/0168-8278(91)90940-D]Search in Google Scholar
[12. MONCRIEF K., KAUFMAN S. Splenic baroreceptors control splenic afferent nerve activity. Am J Physiol Regul Integr Comp Physiol. 2006; 290(2):R352-6.10.1152/ajpregu.00489.200516210416]Search in Google Scholar
[13. GUARNER C., SORIANO G., TOMAS A., BULBENA O., NOVELLA MT., BALANZO J., et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology. 1993; 18(5):1139-43.10.1002/hep.1840180520]Search in Google Scholar
[14. ANGELI P. Hepatorenal syndrome. In: Vincent J-L 2006 Yearbook of Intensive Care and Emergency Medicine. Ed. Springer- Verlag, Berlin, 2006; p. 661-70.10.1007/3-540-33396-7_61]Search in Google Scholar
[15. FERNÁNDEZ J., NAVASA M., PLANAS R., MONTOLIU S., MONFORT D., SORIANO G., et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007; 133(3):818-24.10.1053/j.gastro.2007.06.06517854593]Search in Google Scholar
[16. DAGHER L., MOORE K. The hepatorenal syndrome. Gut. 2001;4 9(5):729-37.10.1136/gut.49.5.729172849211600480]Search in Google Scholar
[17. NIETSCH HH. Management of portal hypertension. J Clin Gastroenterol. 2005; 39(3):232-6.10.1097/01.mcg.0000152783.22266.3515718866]Search in Google Scholar
[18. GENZINI T., TORRICELLI FC. Hepatorenal syndrome: an update. Sao Paulo Med J. 2007; 125(1):50-6.10.1590/S1516-31802007000100010]Search in Google Scholar
[19. SUZUKI H., STANLEY AJ. Current management and novel therapeutic strategies for refractory ascites and hepatorenal syndrome. QJM. 2001; 94(6):293-300.10.1093/qjmed/94.6.29311391027]Search in Google Scholar
[20. KASHANI A., LANDAVERDE C., MEDICI V., ROSSARO L. Fluid retention in cirrhosis: pathophysiology and management. QJM. 2008; 101(2):71-85.10.1093/qjmed/hcm12118184668]Search in Google Scholar
[21. GINÈS P., TORRE A., TERRA C., GUEVARA M. Review article:pharmacological treatment of hepatorenal syndrome. Aliment Pharmacol Ther. 2004; 20(Suppl 3):57-62; discussion 63-4.10.1111/j.1365-2036.2004.02115.x15335404]Search in Google Scholar
[22. GINÈS P., CÁRDENAS A., ARROYO V., RODÉS J. Management of cirrhosis and ascites. N Engl J Med. 2004; 350(16):1646-54.10.1056/NEJMra03502115084697]Search in Google Scholar
[23. MARRERO J., MARTINEZ FJ., HYZY R. Advances in critical care hepatology. Am J Respir Crit Care Med. 2003; 168(12):1421-6.10.1164/rccm.200303-361UP14668256]Search in Google Scholar
[24. RUNYON BA., AASLD PRACTICE GUIDELINES COMMITTEE. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009; 49(6):2087-107.10.1002/hep.2285319475696]Search in Google Scholar
[25. SOLANKI P., CHAWLA A., GARG R., GUPTA R., JAIN M., SARIN SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003; 18(2):152-6.10.1046/j.1440-1746.2003.02934.x12542598]Search in Google Scholar
[26. DUNDAR HZ., YILMAZLAR T. Management of hepatorenal syndrome. World J Nephrol. 2015; 4(2): 277-286.10.5527/wjn.v4.i2.277441913825949942]Search in Google Scholar
[27. MARTÍN-LLAHÍ M., PÉPIN MN., GUEVARA M., DIAZ F., TORRE A., MONESCILLO A. et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008; 134(5):1352-9.10.1053/j.gastro.2008.02.02418471512]Search in Google Scholar
[28. KALAMBOKIS G., ECONOMOU M., FOTOPOULOS A., AL BOKHARHII J., PAPPAS C., KATSARAKI A., et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol. 2005; 100(4):879-85.10.1111/j.1572-0241.2005.40899.x15784036]Search in Google Scholar
[29. DAVENPORT A., AHMAD J., AL-KHAFAJI A., KELLUM JA., GENYK YS., NADIM MK. Medical management of hepatorenal syndrome. Nephrol Dial Transplant. 2012; 27(1):34-41.10.1093/ndt/gfr73622287700]Search in Google Scholar
[30. TURBAN S., THULUYATH PJ., ATTA MG. Hepatorenal syndrome. World J Gastroenterol. 2007; 13(30):4046-55.10.3748/wjg.v13.i30.4046420530417696221]Search in Google Scholar
[31. LOW G., ALEXANDER GJ., LOMAS DJ. Hepatorenal syndrome: aetiology, diagnosis, and treatment. Gastroenterol Res Pract. 2015; 2015:207012.10.1155/2015/207012430636425649410]Search in Google Scholar
[32. VOLK ML., MARRERO JA. Advances in critical care hepatology. Minerva Anestesiol. 2006; 72(5):269-81.]Search in Google Scholar
[33. KAPTANOGLU L., BLEI AT. Current status of liver support systems. Clin Liver Dis. 2000; 4(3):711-29, 34. BRENSING KA., TEXTOR J., PERZ J., SCHIEDERMAIER P., RAAB P., STRUNK H., et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000; 47(2):288-95.10.1136/gut.47.2.288]Search in Google Scholar
[35. SEN S., MOOKERJEE RP., DAVIES NA., WILLIAMS R., JALAN R. Review article: the molecular adsorbents recirculating system (MARS) in liver failure. Aliment Pharmacol Ther. 2002; 16(Suppl 5):32-8.10.1046/j.1365-2036.16.s5.5.x]Search in Google Scholar
[36. WIKLUND RA. Preoperative preparation of patients with advanced liver disease. Crit Care Med. 2004; 32(4 Suppl):S106-15.10.1097/01.CCM.0000115624.13479.E6]Search in Google Scholar
[37. SOLIS-HERRUZO JA., DURAN A., FAVELA V., CASTELLANO G., MADRID JL., MUÑOZ-YAGÜE MT., et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol. 1987; 5(2):167-73.10.1016/S0168-8278(87)80569-X]Search in Google Scholar
[38. TANDON P., BAIN VG., TSUYUKI RT., KLARENBACH S. Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials. Aliment Pharmacol Ther. 2007; 25(9):1017-28.10.1111/j.1365-2036.2007.03303.x17439502]Search in Google Scholar
[39. ALESSANDRIA C., OZDOGAN O., GUEVARA M., RESTUCCIA T., JIMÉNEZ W., ARROYO V., et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology. 2005; 41(6):1282-9.10.1002/hep.2068715834937]Search in Google Scholar
[40. SCHEPKE M., APPENRODT B., HELLER J., ZIELINSKI J., SAUERBRUCH T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int. 2006; 26(7):834-9. 10.1111/j.1478-3231.2006.01302.x16911466]Search in Google Scholar